XCancer

Breast Cancer PSMA PET

Description:

The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.

Sponsor:

University of Iowa

Phase:

Early Phase 1

Contacts:

Elina Shrestha (CONTACT)

eshrestha@uiowa.edu

319 335 0114

Ahmad Shariftabrizi, M.D. (CONTACT)

ashariftabrizi@uiowa.edu

319-887-4942

Government Study Link:

NCT06586047 - Click here to see study on

ClinicalTrials.gov

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

DCFPyL

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Inclusion
  • Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.
  • Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
Exclusion

Exclusion Criteria Not Yet Provided